Alexion Overview
- Founded
-
1992

- Status
-
Acquired/Merged
- Employees
-
3,981

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$41.1B
Alexion General Information
Description
Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating conditions. The company is involved in biotechnology research and offers therapies that treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) among others, enabling individuals to overcome the issues they face every day.
Contact Information
Website
www.alexion.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Primary Office
- 121 Seaport Boulevard
- Boston, MA 02210
- United States
+1 (475) 000-0000
Alexion Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Merger/Acquisition | 21-Jul-2021 | $41.1B | 000.00 | Completed | Profitable | |
6. Merger/Acquisition | 06-Dec-2019 | Cancelled | Profitable | |||
5. PIPE | 10-Mar-2018 | Completed | Profitable | |||
4. PIPE | 06-Aug-2017 | Completed | Profitable | |||
3. 2PO | 23-May-2012 | 00000 | Completed | Profitable | ||
2. IPO | 28-Feb-1996 | Completed | Profitable | |||
1. Early Stage VC | 01-Jan-1994 | Completed | Product Development |
Alexion Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating
Drug Discovery
Boston, MA
3,981
As of 2022
00.00
0000-00-00
000000&0
Alexion Competitors (48)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Prometheus Laboratories | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 | |
000000000000 | Formerly VC-backed | Mountain View, CA | 000 | 00000 | 000000&0 | 00000 |
0000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 | 00000 |
000000 | Corporation | Malvern, PA | 00 | 000.00 | 000000000 | 000.00 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
Alexion Patents
Alexion Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2021364779-A1 | Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase | Pending | 21-Oct-2021 | ||
CA-3178003-A1 | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors | Pending | 20-Aug-2021 | ||
CA-3177998-A1 | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor | Pending | 20-Aug-2021 | ||
CA-3177165-A1 | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) | Pending | 14-Jun-2021 | ||
US-20220399087-A1 | Method and system for improved management of genetic diseases | Pending | 11-Jun-2021 | G16H20/10 |
Alexion Executive Team (47)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Sean Christie | Chief Financial Officer & Administrative Officer | ||
Daniel Bazarko | Senior Vice President, Finance & Chief Accounting Officer | ||
John Orloff MD | Executive Vice President & Head of Research & Development | ||
Scott Weintraub | Vice President, Global Marketing & Head of Global Commercial Strategy | ||
Venu Nagali | Vice President, Finance and Value Creation |
Alexion Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
John Mollen | Self | Board Member & Chairman of Leadership and Compensation Committee | 000 0000 |
Alexion Signals
Alexion Former Investors (17)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Alkeon Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
BB Biotech | Asset Manager | Minority | 000 0000 | 000000 0 | |
BMO Financial Group | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | |
Bank of the West | Corporation | Minority | 000 0000 | 000000 0 | |
CHL Medical Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Alexion Investments & Acquisitions (25)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 0000 | 16-Nov-2022 | 0000000000 | 0000 | Biotechnology | 0000 0000 |
000000 000000 | 06-Oct-2021 | 0000000000 | 00000 | Biotechnology | |
000000 000000 | 01-Feb-2021 | 000000000 | 000.00 | Buildings and Property | 00000000 |
0000000 00000 | 02-Jul-2020 | 0000000000 | 00.000 | Pharmaceuticals | 000000 00 |
Achillion | 28-Jan-2020 | Merger/Acquisition | 00.000 | Pharmaceuticals | 000000 00 |
Alexion Subsidiaries (3)
Company Name | Industry | Location | Founded |
---|---|---|---|
Caelum Biosciences | Biotechnology | Bordentown, NJ | 2015 |
0000000000 000000 | Drug Discovery | Amsterdam, Netherlands | 0000 |
000000000 | Drug Discovery | Milford, MA | 0000 |
Alexion Exits (4)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00000 000000000000 | 09-Sep-2019 | 0000 | 0000 | Completed |
|
0000000 0000000000 | 05-Jan-2015 | 00000 00000 00 | 00000 | Completed |
|
0000000 0000000000 | 22-Jan-2014 | 00000 00000 00 | 00000 | Completed |
|
PhaseRx | 02-Oct-2013 | Convertible Debt | 00.00 | Completed |